Run your own memo
Real deck · named companyPublished 2026-09-09

Theranos

This memo was written from the 2006 deck and the sources available then. Nothing that happened later was used.

Verdict

PASS

Confidence · Highnothing here reopens it

Technology unverified, math broken, customers unnamed.

Six deals across five unnamed companies in validation phase cannot be verified, the $50M per-trial revenue figure is arithmetically inconsistent with the deck's own $7,500 per-patient fee, and the FDA regulatory pathway is entirely absent from a deck pitching a diagnostic device for use in regulated clinical trials.

The technology may be real, but this deck provides no evidence that it is.

StageSeries B
SectorHealthcare / Diagnostics
Market$39B per year

Why this stage

  • ·The deck states a Series B round with $30M offering ($15-20M to existing investors, $10-15M to new investors).
  • ·This size and structure is consistent with Series B capital deployment.
  • ·The company has 50 employees, 6 deals across 5 companies in validation phase, and $120M-$1.5Bn in projected revenue from existing deals, indicating post-seed traction sufficient for Series B.
  • ·No material contradictions between traction and round size are evident.

The one blocker

Core technology claims entirely unverified.

Grades

4 axes
B5/10Unicorn opportunity

The Phase IV monitoring market is large and underserved, but the deck's $39B TAM is overstated by 2-3x on its own arithmetic (derived), and the realistic monitoring-services slice is not established.

the full reasoning
  • The market problem is genuine and the post-Vioxx regulatory environment creates real demand for proactive monitoring infrastructure.
  • A corrected TAM of $13B-$20B (derived) is still a large market, and the per-patient recurring fee model scales without proportional COGS growth once readers are deployed.
  • What holds this to a 5 rather than a 7 is the absence of any evidence that the market concentrates on one winner: central lab CROs are entrenched, Abbott and Biosite have the scale to enter if the market develops, and Theranos has no disclosed IP, no FDA clearance, and no named customer to anchor a winner-take-most argument.
  • A 7 or 8 becomes available when independent validation is published and at least one named pharma sponsor is on record, because the informatics switching cost argument becomes real at that point.
C+4/10Capital efficiency

The $30M raise funds manufacturing scale-up and sales force expansion with no disclosed allocation, no runway calculation, and no milestone map, making it impossible to assess whether the capital reaches the next defensible milestone.

the full reasoning
  • The use of funds is described in one sentence: rapid scaling of production and manufacturing infrastructure and sales force expansion.
  • No line-item budget, no headcount plan, and no runway calculation are disclosed.
  • The category norm for a pre-revenue diagnostic hardware company at Series B includes significant capital requirements for manufacturing tooling, regulatory affairs, and clinical validation, none of which are costed here.
  • The 70% stated gross margin is consistent with Biosite's 71% at scale, which suggests the model is capital-efficient once at volume, but the path to volume requires FDA clearance and at least one signed contract, neither of which is funded in a disclosed way.
  • A 4 reflects a workable but undisclosed capital plan; a 6 becomes available when a 24-month budget with milestone anchors is provided.
B5/10Team velocity

The senior operating team carries genuine domain credentials, Howard Bailey's CFO track record, Diane Parks's Genentech relationships, Ian Gibbons's immunoassay development depth, but the company has been operating since 2003 and has not disclosed a single shipped product, cleared regulatory filing, or signed contract.

the full reasoning
  • Elizabeth Holmes founded Theranos in 2003 at age 19, left Stanford during her sophomore year, and has assembled a senior team that would not have joined without conviction in the technology.
  • Howard Bailey took QED and Photon Dynamics public; Diane Parks ran biotherapeutics at Genentech; Ian Gibbons brings decades of immunoassay development at Syva and AmCell.
  • These are not decorative credentials.
  • What the deck cannot show, three years into the company's life, is a shipped product, a cleared regulatory filing, or a signed commercial contract.
  • The absence of any of these is not a stage-normal condition at Series B, it is the central question about velocity.
  • A 7 becomes available when the platform clears FDA and at least one deal converts from validation to contract, because at that point the team's ability to move a complex regulated product through the system is demonstrated.
C3/10Moat durability

The claimed moat, on-chip chemiluminescence, integrated informatics, and assay development speed, is entirely contingent on the technology performing as claimed, and no independent validation exists to confirm it does.

What moves this grade

A 7 or 8 requires demonstrated switching costs from a signed, multi-year pharma sponsor contract.

the evidence
  • The deck identifies three potential moat sources: analytical sensitivity from on-chip chemiluminescence, switching costs from the integrated cartridge-reader-informatics workflow once embedded in a sponsor's trial protocol, and assay development speed of three months for new analytes.
  • If the technology is real, the informatics switching cost is the most durable of the three: a pharma sponsor who has redesigned a trial protocol around the ABCS platform faces meaningful cost and regulatory risk to switch back to central lab CROs.
  • The problem is that none of these advantages can be assessed without independent validation, and the IP portfolio, the one moat that would hold under a funded attack from Abbott or Biosite, is entirely undisclosed.
  • A 3 reflects a moat that is real in the deck's narrative and unverifiable in the evidence.
  • A 6 becomes available when the technology is validated and at least one patent is disclosed with a freedom-to-operate opinion.

Flags

7 flags · 2 critical
01

Slide 14 states average Theranos revenue per trial is $50M, but this figure is not derived from the stated $7,500 per-patient fee and patient count ranges (2,000-10,000 patients per trial); the math does not reconcile.

02

Slide 2 states immediate goal is to become the standard for improving efficacy and risk/benefit and safety profile of every therapy, but deck does not address regulatory approval pathway, clinical validation requirements, or FDA clearance status for the diagnostic platform.

03

Slide 3 projects $120M-$300M revenue in next 1.5 years from 6 current deals plus 15 pipeline deals, but slide 3 also states existing deals alone project $120M-$1.5Bn in revenue; the two ranges overlap but are not reconciled.

+ 4 more in the full memo

Do next

Pass pending independent analytical validation and FDA filing.

Independent peer-reviewed analytical validation of the ABCS platform, a disclosed FDA clearance filing with a timeline, and at least one named pharma sponsor with a signed contract would reopen this as an Invest.

The full memo

The complete read, with the market and diligence, is built for desktop. Open Verdict on a computer for the full analysis.